Latest From TransMedics Inc.
TransMedics Organ Care System helps to preserve lungs for transplant, and was recommended for approval despite significant US FDA concerns over trial conduct.
Two US FDA advisory committee meetings are scheduled for May. One will delve into a new organ-transplant device intended to keep organs viable longer, while the other will present recommendations on how the agency should spend funds from the 21st Century Cures Act.
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June.
- Medical Devices
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- TransMedics Inc.
- Senior Management
Waleed Hassanein, MD, Pres. & CEO
Stephen Gordon, CFO
Tamer Khayal, MD, CMO
Neal Beswick, VP, Bus. Dev.
Marienne Sanders, VP, Global Mktg.
- Contact Info
Phone: (978) 552-0900
200 Minuteman Rd.
Andover, MA 01810
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.